HK inno.N Says Its K-CAB Obtained Regulatory Approval from Peru

HK inno.N Corp. announced on July 24 that its new drug for gastroesophageal reflux disease, K-CAB (active ingredient: Tegoprazan), has been granted product approval by Peru's National Medicines Authority (DIGEMID) on July 21.

In 2018, the company inked a contract with “Laboratorios Carnot,” a leading pharmaceutical company in Central and South America, covering 17 countries, including Peru, to export finished KeiCap products.

The Peruvian market name for K-CAB is “Ki-CAB” and it is designated for use in four therapeutic indications: treatment of erosive gastroesophageal reflux disease, treatment of non-erosive gastroesophageal reflux disease, treatment of gastric ulcers, and antibiotic combination therapy for eradicating Helicobacter pylori in patients with peptic ulcers and chronic atrophic gastritis.

K-CAB has already been introduced to 35 countries worldwide, including the United States, China, India, and several Central and South American nations, through either technology export or the export of finished pharmaceutical products.

Among the 35 countries, K-CAB has been launched in China, Mongolia, the Philippines, Mexico, and Indonesia. The drug is currently undergoing preparations for launch in Singapore and Peru, while it is undergoing phase 3 clinical trials in the United States.